What Mayo Clinic does

Mayo Clinic is a not-for-profit academic medical center founded in 1864 and headquartered in Rochester, Minnesota, with additional major campuses in Jacksonville, Florida and Scottsdale/Phoenix, Arizona. It delivers integrated tertiary and quaternary specialty patient care across oncology, cardiology, transplant, neurology, and rare disease programs, and runs the Cancer CARE Beyond Walls at-home chemotherapy program serving patients within a 75-mile radius of the Florida campus. The organization reported $1.5 billion in net income last year, a 13% year-over-year increase, under CEO Gianrico Farrugia's leadership, which is set to transition at the end of 2026.

The Mayo Clinic Platform anchors a portfolio of AI products built on de-identified patient data, including more than 17 million digitized pathology slides, three decades of EHR data on over 22,000 patients, and a network of 3,100+ digital pathology clients across 55 countries. Validated proprietary models include the REDMOD pancreatic cancer detection AI (73% sensitivity at a median 16 months before clinical diagnosis), the PSA Control Tower for prostate cancer monitoring, Meningioma AI, Primary Aldosteronism screening (XGBoost, >90% sensitivity), and a co-developed frontier AI model with Microsoft that Mayo Clinic owns and will distribute globally through Azure Foundry APIs. Mayo Clinic also collaborates with Abridge, Bayesian Health, Techcyte, Opmed, Onymos, Klick Labs, and others, and is preparing HL7 FHIR APIs for the January 1, 2027 CMS-0057-F interoperability deadline.

Mayo Clinic generates revenue primarily through patient care services, supplemented by philanthropic gifts (e.g., a $75 million gift from the Ringhaver family), federal and state research grants, content and AI model licensing (bswift Evive, Mesoblast CAR technology), and strategic equity investments in companies such as Sana Biotechnology ($25 million), WHOOP, Techcyte, and Syntax Bio. The organization is pursuing the multibillion-dollar "Bold. Forward. Unbound." expansion of its Rochester campus alongside capabilities in Arizona and Florida, and has recently ended remote-only job postings in favor of hybrid arrangements within 100 miles of work sites.

Name

Mayo Clinic

Legal name

Mayo Clinic

Website

https://www.mayoclinic.org

Company type

Private

Founded year

1864

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Mayo Clinic is a not-for-profit academic medical center headquartered in Rochester, Minnesota, delivering integrated specialty patient care, biomedical research, and AI-enabled clinical decision support tools across campuses in Minnesota, Florida, and Arizona.

Ownership category

akta.pro rank

Product category

Integrated Healthcare Services

NAICS

General Medical and Surgical Hospitals (622110)

SIC

Services-General Medical & Surgical Hospitals, Nec (8062), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Hospitals, Clinics & Charitable Healthcare Providers (BPAGACAB)

Keywords

• Integrated healthcare services
• Clinical research
• AI medical diagnostics
• Digital pathology
• Specialty medical care

Headquarters

HQ city

Rochester

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Others

Revenue model

1. Patient Care Services: Primary revenue stream from hospital and clinical services including the Mayo Clinic Comprehensive Cancer Center and Cancer CARE Beyond Walls at-home chemotherapy program; reported $1.5 billion in net income last year, a 13% increase from the prior year.
2. AI Model Licensing & Distribution: Revenue from owning the frontier healthcare AI model and making it available globally via Microsoft Azure Foundry APIs to other healthcare organizations. Mayo Clinic retains a financial interest in referenced technologies and uses revenue to support its not-for-profit mission.
3. Health Content Licensing: Licensing of clinically vetted health education content (e.g., to bswift for integration into the Evive personalized recommendation engine) and provision of Mayo Clinic Platform with de-identified data for partner integrations.
4. Philanthropic Donations: Major philanthropic gifts such as the $75 million gift from Paula and Randy Ringhaver to Mayo Clinic in Florida supporting the Bold. Forward. Unbound. initiative and the Lee Ringhaver Tower expansion.
5. Research Grants: Federal and state research funding including $1.5 million from the Ed and Ethel Moore Alzheimer's Disease Research Program to Mayo Clinic Jacksonville across five projects, and a $300,000 federal grant to develop the AI smartwatch tantrum predictor.
6. Strategic Equity Investments: Strategic equity investments in biotech and healthtech companies such as the $25 million equity investment in Sana Biotechnology (with options for an additional $25 million) and participation in funding rounds for Syntax Bio, Sub-Q Bionics, Star51 Capital, and WHOOP.

Pricing tiers

Go-to-market motion5 records

Distribution channels7 records

Marketing channels7 records

Core offering

Mayo Clinic is a not-for-profit integrated health system that delivers tertiary and quaternary clinical care across its Minnesota, Arizona, and Florida campuses and through at-home programs such as Cancer CARE Beyond Walls, conducts biomedical research, and licenses AI models, digital pathology assets, clinical content, and patented CAR and other IP to commercial healthcare partners. Its Mayo Clinic Platform monetizes three decades of de-identified patient data through the Microsoft Azure Foundry AI model and direct data/integration partnerships.

Product overview

Mayo Clinic operates as an integrated platform combining clinical care delivery, research, and AI-enabled product offerings. Its core research foundation is the Mayo Clinic Platform, which leverages de-identified patient data including lab results, clinical notes, imaging, and pathology to build and continuously improve predictive models. Building on this foundation, Mayo Clinic has developed a portfolio of AI products including REDMOD (pancreatic cancer detection AI), the PSA Control Tower (prostate cancer monitoring), the Meningioma AI Classification System, the Primary Aldosteronism Screening AI Model, and the AI-Powered Smartwatch App for child temper tantrum prediction. Mayo Clinic has also partnered with Microsoft to develop a frontier AI model for healthcare, owned by Mayo Clinic and distributed through Azure Foundry APIs. Beyond AI diagnostics, Mayo Clinic offers clinical care delivery programs such as Cancer CARE Beyond Walls (at-home chemotherapy), the Mayo Clinic Comprehensive Cancer Center, and the Mayo Clinic-ASU Health Care Accelerator. Supporting infrastructure includes the Mayo Clinic Digital Pathology ecosystem (MCDP) with over 17 million digitized pathology slides, and the Optiscan digital endomicroscopic imaging system for robotic-assisted breast surgery. These products collectively represent Mayo Clinic's transition toward AI-augmented precision medicine, with integration into clinical workflows via partnerships with vendors like Abridge, Bayesian Health, Onymos, bswift Evive, Klick Labs, Opmed, Techcyte, and others.

Differentiator

Problem solved

Functional benefit

Brands

• Mayo Clinic Platform: Data and AI platform leveraging de-identified patient data including lab results, clinical notes, imaging, and pathology to build predictive models.
• Mayo Clinic Digital Pathology
• Cancer CARE Beyond Walls
• Mayo Clinic–ASU Health Care Accelerator
• Mayo Clinic Proceedings
• Mayo Clinic Proceedings: Digital Health
• Mayo Clinic Comprehensive Cancer Center
• Mayo Clinic Arizona
• Mayo Clinic in Florida
• Mayo Clinic Jacksonville
• Bold. Forward. Unbound.

Products and services

• REDMOD AI Model for Pancreatic Cancer Detection Radiomics-based AI model developed at Mayo Clinic that analyzes routine abdominal CT scans to detect pancreatic ductal adenocarcinoma approximately 16 months (median) before clinical diagnosis by identifying subtle tissue changes; achieved 73% sensitivity vs. ~39% for radiologists on the same scans, currently being validated in the AI-PACED prospective clinical trial.
• Mayo Clinic-Microsoft Frontier AI Model for Healthcare Frontier AI model owned by Mayo Clinic and co-developed with Microsoft, trained on Mayo's de-identified clinical data and medical expertise; synthesizes medical images, lab results, longitudinal patient history, and imaging data to support earlier diagnoses, personalized treatment decisions, and clinical reasoning for healthcare organizations worldwide via Azure Foundry APIs.
• PSA Control Tower AI-powered intelligent monitoring tool developed by Mayo Clinic Department of Radiation Oncology that tracks prostate-specific antigen (PSA) trends in patients after prostate cancer treatment and flags early signs of recurrence; powered by Mayo Clinic Platform with de-identified patient data including lab results, clinical notes, imaging, and pathology.
• Mayo Clinic Digital Pathology Integrated innovation ecosystem advancing digital pathology across clinical care and research, with investments in emerging companies (Conflux and ViewsML); leverages a repository of more than 17 million digitized pathology slides across a global network of over 3,100 clients in 55 countries.
• Cancer CARE Beyond Walls At-home chemotherapy and cancer treatment program at Mayo Clinic in Florida, combining virtual care, remote monitoring, and in-home clinical services through trained home health nurses and a central command center; patients eligible if they live within 75 miles of Mayo Clinic Comprehensive Cancer Center.
• Meningioma AI Classification System AI system developed at Mayo Clinic that analyzes routine pathology slides to classify meningiomas and predict tumor recurrence risk using deep learning models trained on data from 672 patients; published in The Lancet Digital Health, capable of reducing reliance on specialized genetic testing.
• Primary Aldosteronism Screening AI Model XGBoost-based AI model trained on three decades of EHR data from over 22,000 patients to detect primary aldosteronism (PA), achieving over 90% sensitivity in confirmed cases while flagging approximately two-thirds of a 225,887-patient hypertensive cohort up to a year before traditional diagnosis.
• AI-Powered Smartwatch App for Child Temper Tantrum Prediction Smartwatch app developed at Mayo Clinic that monitors children's heart rates and restlessness to predict temper tantrums; alerted parents within 4 seconds with 81% accuracy up to 60 minutes in advance, and reduced average tantrum duration from 22 minutes (therapy alone) to 10 minutes in a study of 50 children.
• Bayesian Health AI Palliative Care Platform AI-powered platform co-developed with Bayesian Health to identify hospitalized patients who may benefit from palliative care earlier in their stay; integrated directly into the EHR workflow, demonstrated 44% increase in timely palliative care referrals, 25% reduction in 60-day readmissions, and 28% reduction in 90-day readmissions.
• Opmed Multimodal AI Scheduling Platform Multimodal deep learning platform validated with Mayo Clinic for cardiovascular procedure scheduling, achieving Mean Absolute Error of 0.564 hours vs. human baseline of 1.13 hours per surgical case, reducing scheduling errors by approximately 50% and reclaiming over 200 wasted operating room hours annually per room.
• Mayo Clinic-ASU Health Care Accelerator Joint accelerator program between Mayo Clinic and Arizona State University that bridges healthcare innovations from prototype to clinical deployment at scale, with industry partners such as Intel supporting technology development.
• 3D-Bioprinted Human Skin Model 3D-bioprinted human skin model using living human cells and plant-based recombinant collagen that can survive for weeks, offering a biologically relevant alternative to traditional animal testing for preclinical drug research; reviewed by the FDA.
• Remote Patient Monitoring for Lung Transplant Recovery Remote patient monitoring system studied at Mayo Clinic for detecting early health complications in lung transplant recipients during their first year after discharge; in a 12-month study of 116 patients it generated nearly 470 alerts, approximately 25% of which led to immediate care changes.
• Rapid Lateral Flow Assay for Coccidioidomycosis Rapid lateral flow assay using fingerstick capillary blood to detect anti-coccidioidal antibodies in patients with coccidioidomycosis; produces results in 10 minutes compared to 2–7 day turnaround for standard reference laboratory testing, with 89.5% positive agreement with immunodiffusion testing.
• Optiscan Digital Endomicroscopic Imaging System Digital endomicroscopic imaging system for robotic-assisted breast surgery developed through Know-How Agreement with Mayo Clinic; all key engineering milestones and development objectives completed, currently undergoing preclinical testing with agreement extended through 12 August 2026.
• Mayo Clinic Comprehensive Cancer Center Cancer research and treatment center where researchers will present more than 30 studies at the 2026 ASCO Annual Meeting covering precision oncology, early cancer detection, AI, and personalized cancer care; operates across Mayo Clinic's Minnesota, Florida, and Arizona campuses.

Quantifiable outcome

• 73% detection rate (vs. 39% for radiologists) for pancreatic cancer on routine CT scans at median 16 months before diagnosis
• +9 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration16 records

AI capability31 records

Feature11 records

Partnerships

25 partnerships are on record, tiered core, minor and flagship.

• CogniviacoreStrategic or Co-development Partner · 23 June 2026Collaboration announced to advance behavioral intelligence across clinical research and medical practice. Initially focuses on three key determinants: therapeutic non-adherence, missed appointments, and clinical trial retention. Aims to make patient behavior measurable and actionable. Mayo Clinic has a financial interest in the referenced technology and uses revenue to support its not-for-profit mission.
• OpmedcoreStrategic or Co-development Partner · 18 June 2026Multi-year collaborative validation study presented at ACC.26 demonstrating that Opmed's multimodal deep learning platform reduces cardiovascular procedure scheduling errors by approximately 50%, achieving Mean Absolute Error of 0.564 hours vs. 1.13 hours for human baseline, and reclaims over 200 wasted OR hours annually per room.
• Klick LabscoreStrategic or Co-development Partner · 15 June 2026Series of clinical studies at Mayo Clinic in Florida to explore vocal biomarkers for identifying chronic diseases. Builds on 2023 Mayo Clinic Proceedings: Digital Health study showing 89% accuracy for women and 86% for men in distinguishing Type 2 diabetes from 10 seconds of voice data. Joint research on hypertension, ovulation, and blood glucose patterns.
• Echo IQcoreStrategic or Co-development Partner · 12 June 2026Research collaboration to evaluate Echo IQ's AI platform for cardiac risk stratification in oncology patients undergoing cancer therapy. Study to be conducted at Mayo Clinic Arizona under Dr. Chadi Ayoub; results expected in first half of 2027.
• KardiganminorOEM/ Whitelabel/ Licensing Partner · 11 June 2026Kardigan's ataciguat (licensed from Sanofi and Mayo Clinic) is being developed for calcific aortic valve stenosis with $80-90 million in IPO proceeds allocated to its development. Kardigan completed its Nasdaq IPO raising $400 million.
• bswiftcoreOEM/ Whitelabel/ Licensing Partner · 9 June 2026Licensing agreement to integrate Mayo Clinic's clinically vetted health education content into bswift's Evive™ personalized recommendation engine. Combines Mayo Clinic's clinical expertise with bswift's personalization algorithms to improve employee health engagement.
• Samsung MedisoncoreTechnology or Integration · 8 June 2026Supply agreement for HERA Z20 obstetrics and gynecology ultrasound systems to Mayo Clinic's maternal-fetal medicine division. Strengthens Samsung Medison's position in future U.S. hospital bids as North American revenue grew from 16.4 billion won (2023) to 27.7 billion won (2025).
• MicrosoftflagshipStrategic or Co-development Partner · 2 June 2026Strategic collaboration announced June 2, 2026 to develop a frontier AI model designed specifically for healthcare. Combines Mayo Clinic's clinical expertise and de-identified health data with Microsoft's AI and cloud capabilities. Mayo Clinic owns the model; Microsoft plans to make it available globally through Azure Foundry APIs. Initially deployed within Mayo Clinic's clinical environment for testing and refinement.
• Optiscan ImagingcoreStrategic or Co-development Partner · 1 June 2026Two-year milestone of Know-How Agreement to develop a digital endomicroscopic imaging system for robotic-assisted breast surgery. All engineering milestones and development objectives completed; Agreement extended until 12 August 2026 to facilitate strategic, clinical, and commercial planning.
• SofyaminorStrategic or Co-development Partner · 1 June 2026Miami-based Sofya completed a program through the Mayo Clinic platform working on AI models for precision oncology focused on prostate cancer; now deploying technology across hospitals in Latin America including Brazil's Hospital Israelita Albert Einstein.
• IlluminaminorStrategic or Co-development Partner · 28 May 2026Mayo Clinic evaluated Illumina's distributed whole-genome sequencing solution for MRD research and found high concordance in preliminary results. Findings to be jointly presented with Bristol Myers Squibb at the 2026 ASCO Annual Meeting.
• Cosm Medical Corp.coreOEM/ Whitelabel/ Licensing Partner · 27 May 2026Licensing and collaboration agreement with Duke Health and Mayo Clinic to develop and commercialize Gynethotics™ Recovery, personalized intravaginal devices for post-surgical pelvic recovery following reconstructive surgery. Cosm Medical licensed intellectual property from both institutions.
• SphairaminorStrategic or Co-development Partner · 20 May 2026Development agreement for autonomous patient shuttles. Sphaira's technology claims to replace two to three transporters per unit and increase efficiency by 200 to 300 percent. The Moby mobile protective bubble system is currently undergoing FDA approval and is in clinical study at Stanford Children's Hospital.
• Conflux and ViewsMLcoreStrategic or Co-development Partner · 20 May 2026Mayo Clinic Digital Pathology collaborations with Conflux and ViewsML as part of an integrated innovation ecosystem leveraging the 17 million+ digitized pathology slide repository and 3,100+ client network across 55 countries.
• Bayesian HealthflagshipStrategic or Co-development Partner · 19 May 2026Co-development of an AI solution to identify hospitalized patients who may benefit from palliative care. Randomized clinical trial at Mayo Clinic demonstrated 44% increase in timely referrals, 25% reduction in 60-day readmissions, and 28% reduction in 90-day readmissions. First collaboration at Mayo Clinic to deploy AI across the entire care process in a complex hospital setting.
• Myosin TherapeuticscoreStrategic or Co-development Partner · 19 May 2026Phase 1/2 STAR-GBM trial for MT-125 (first-in-class non-muscle myosin II inhibitor) for newly diagnosed glioblastoma, conducted across Mayo Clinic's Minnesota, Florida, and Arizona campuses with National Cancer Institute support. MT-125 has Orphan Drug and Fast Track designations.
• GE HealthCarecoreStrategic or Co-development Partner · 8 May 2026First patient dosed at Mayo Clinic in Rochester for the international Phase 2/3 LUMINA clinical trial of GE HealthCare's manganese-based MRI contrast agent mangaciclanol under FDA Fast Track designation. If approved, mangaciclanol could transform the $20+ billion contrast-enhanced MRI market by reducing reliance on rare-earth gadolinium.
• Truth InitiativecoreStrategic or Co-development Partner · 7 May 2026EX Program developed in partnership with Mayo Clinic to help users quit nicotine. Program proven effective in randomized clinical trials published in JAMA Internal Medicine and JAMA, increasing the odds of quitting by up to 40%. Reached 1 million young people ages 13 to 24.
• AbridgecoreTechnology or Integration · 6 May 2026Mayo Clinic deployed Abridge's ambient AI documentation tool for nurses across its network, achieving patient opt-in rates in the high 80 percent and up to 30 minutes of time savings per shift for nurses with highest adoption rates.
• Merck (via multimodal AI collaboration)coreStrategic or Co-development Partner · 5 May 2026Multiyear AI collaboration with Merck & Co. referenced among the company's Q1 2026 strategic AI partnerships alongside Google Cloud and Tempus AI. Part of the broader Merck-Mayo Clinic multimodal AI collaboration cited as a key development in the AI Drug Discovery Infrastructure Market.
• GlycanAgeminorGTM or Marketing Partner · 5 May 2026GlycanAge is hosting a landmark inflammaging conference in Dubrovnik, Croatia, co-organized with Mayo Clinic as part of the ISABS conference series to mark 25 years of inflammaging research.
• OnymoscoreTechnology or Integration · 28 April 2026Collaboration to integrate Onymos' DocKnow intelligent document processing platform into Mayo Clinic's digital infrastructure for precision medicine. Designed to interpret complex clinical information and present structured outputs while maintaining HIPAA, CLIA, and CAP compliance. Plans to evaluate opportunities to extend the approach to other institutions.
• Harvard Apparatus Regenerative TechnologyminorStrategic or Co-development Partner · 27 April 2026First patient treated with the Cellspan™ Esophageal Implant in a Phase 1 feasibility and safety clinical trial at Mayo Clinic in Rochester, Minnesota. The trial will enroll up to ten patients to establish a continuous biological neoconduit by three months post-surgery.
• Mesoblast LtdcoreOEM/ Whitelabel/ Licensing Partner · 14 April 2026Mesoblast acquired exclusive global rights to a patented chimeric antigen receptor (CAR) technology platform from Mayo Clinic by acquiring a Mayo Clinic startup; share-based transaction. The platform enhances mesenchymal stromal cells' ability to target inflamed tissue and support tissue regeneration. Mayo Clinic continues supporting Mesoblast in advancing the technology.
• Aveeno (Kenvue)coreStrategic or Co-development Partner · 10 March 2026Three-year research collaboration announced March 10, 2026 focusing on skin health science, including pre-clinical and clinical investigations targeting skin longevity and regeneration. Revives a 1945 collaboration between the Musher brothers and Mayo Clinic that produced colloidal oatmeal treatments.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Cleveland Clinic: Nonprofit academic medical center comparable to Mayo Clinic in scale, multispecialty care delivery, and brand recognition. Competes directly for complex tertiary/quaternary care cases and is pursuing parallel AI and digital health initiatives.
• Mass General Brigham: Large nonprofit integrated healthcare system in Boston comparable to Mayo Clinic in research output, specialty care, and AI investment. Operates the Mass General Brigham AI platform and is a direct competitor for AI-driven healthcare leadership.
• Johns Hopkins Medicine: Nonprofit academic health system with comparable scale, research output, and reputation. Develops healthcare AI through its inHealth initiative and is a direct competitor for high-acuity patient referrals and biopharma partnerships.
• UCSF Health: Major nonprofit academic medical center in San Francisco comparable in research intensity, AI investment, and specialty care focus. Develops healthcare AI through UCSF Center for Digital Health Innovation.
• Stanford Health Care: Nonprofit academic health system with strong AI research ties to Silicon Valley. Comparable to Mayo Clinic in technology partnerships (e.g., with Microsoft) and pursuit of AI-augmented clinical care.
• NewYork-Presbyterian Hospital: Large nonprofit academic medical center affiliated with Columbia and Cornell. Comparable in patient volume, specialty care breadth, and research output; competing for the same complex patient referrals and digital health partnerships.
• Cedars-Sinai: Nonprofit academic medical center in Los Angeles with comparable brand recognition and research output. Has invested in healthcare AI through its Smidt Heart Institute and Cedars-Sinai Accelerator program.
• Northwestern Medicine: Nonprofit integrated academic health system in Chicago comparable in specialty care delivery and research intensity. Pursuing AI and digital health initiatives across its hospital network.
• NYU Langone Health: Nonprofit academic medical center in New York with comparable research output, specialty care, and recent investments in digital health and AI-driven care delivery.

Broad incumbents

• HCA Healthcare: For-profit hospital operator with significantly larger scale than Mayo Clinic. Provides a broader incumbent benchmark for hospital operations, digital health, and AI investment, but differs in business model (investor-owned) and patient mix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mayoclinic
• Facebookfacebook.com/MayoClinic
• LinkedInlinkedin.com/company/mayo-clinic

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments110 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mayo Clinic